| abstract |
The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticle carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. An embodiment of the chimeric protein comprises of a TLR5 agonist such as a flagellin, and a gpl20-derived peptide. The invention is also directed to methods of internalising an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins. |